Target, across the briefings

TP53 across 47 cancers

TP53 is on the target list of 47 of the briefings. No drug aimed at it carries an FDA label naming any of them. In the reference cohorts of the 44 with a mutation landscape it is altered in at least 5% of patients in 36 and in under 2% in 3 (Myeloproliferative neoplasms, Testicular cancer, Thyroid cancer) — a target there by expression, dependency or drug label, not by mutation.

DiseaseLabel statusFurthest stage (Open Targets)Distinct drugsCell-therapy trialsAltered in the reference cohort
Acute lymphoblastic leukemiaphase 38—4.38% mut · 0.15% amp · 0.29% del n=137
Acute myeloid leukemiaphase 38—7.5% mut · 0.52% amp · 1.05% del n=200
Anal cancerphase 38—10.07% mut · 0.72% del n=139
Basal cell carcinomaphase 38—64.83% mut n=236
Bladder cancerphase 38—48.78% mut · 1.72% del n=410
Breast cancerphase 38—32.46% mut · 0.84% del n=1066
Burkitt lymphomaphase 38—no landscape
Cervical cancerphase 38—7.9% mut · 1.02% del n=291
Cholangiocarcinomaphase 38—35.25% mut n=417
Chronic lymphocytic leukemiaphase 38—8.19% mut n=1074
Chronic myeloid leukemiaphase 38—no landscape
Colorectal cancerphase 38—58.43% mut · 1.35% del n=534
Cutaneous squamous cell carcinomaphase 38—66.27% mut n=83
Diffuse large B-cell lymphomaphase 38—9.29% mut n=1001
Endometrial cancerphase 38—37.14% mut · 0.19% amp · 0.38% del n=517
Esophageal cancerphase 38—86.81% mut · 0.55% amp · 1.1% del n=182
Ewing sarcomaphase 38—11.65% mut n=103
Gallbladder cancerphase 38—63.95% mut n=233
Gastric cancerphase 38—48.62% mut · 0.23% amp · 1.14% del n=436
Gastrointestinal stromal tumourphase 38—4.48% mut · 0.64% del n=469
Glioblastomaphase 38—30.77% mut · 0.87% del n=390
Head and neck cancerphase 38—68.54% mut · 0.58% del n=515
Hepatocellular carcinomaphase 38—29.51% mut · 2.45% del n=366
Lower-grade gliomaphase 38—48.25% mut · 0.39% amp · 0.39% del n=514
Lung cancerphase 38—50.71% mut · 1.17% del n=566
Mantle cell lymphomaphase 38—17.24% mut n=29
Marginal zone lymphomaphase 38—6.98% mut n=43
Medulloblastomaphase 38—3.46% mut n=491
Merkel cell carcinomaphase 38—24.65% mut n=142
Mesotheliomaphase 38—16.28% mut n=86
Multiple myelomaphase 38—7.32% mut n=205
Myelodysplastic syndromesphase 38—11.74% mut n=3323
Myeloproliferative neoplasmsphase 38—1.99% mut n=151
Nasopharyngeal carcinomaphase 38—12.5% mut n=56
Osteosarcomaphase 38—22.63% mut · 1.23% amp · 6.17% del n=137
Ovarian cancerphase 38—70.94% mut · 1.22% amp · 0.35% del n=523
Pancreatic cancerphase 38—59.78% mut · 0.55% del n=179
Prostate cancerphase 38—11.54% mut · 4.29% del n=494
Rhabdomyosarcomaphase 38—2.33% mut n=43
Small cell lung cancerphase 38—84.17% mut n=120
Small intestine cancerphase 38—53.95% mut · 0.66% del n=152
Soft tissue sarcomaphase 38—33.33% mut · 0.4% amp · 9.88% del n=255
Testicular cancerphase 38—0.67% mut n=149
Thyroid cancerphase 38—0.41% mut · 0.4% del n=489
Vulvar cancerphase 38—33.33% mut n=15
Waldenström macroglobulinaemiaphase 38—no landscape
Wilms tumourphase 38—2.3% mut · 0.81% del n=652

"Approved here" means a drug Open Targets records as aimed at TP53 carries an FDA label that names that disease, per the briefing's openFDA stage. "Approved elsewhere" means the drug is approved for some other indication. Stage is the furthest Open Targets clinical stage among drugs aimed at the gene, in any indication; the database is reported as it is, and it lags some approvals. Cell-therapy trials are counted on the antigen the briefing maps the gene to, from ClinicalTrials.gov. The last column is the disease's mutation landscape: non-silent mutation, high-level amplification and deep deletion as percentages of the reference cohort's patients, each over its own denominator; "not on panel" means the reference cohort could not have called the gene.